Paper Details

Paper Title

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

Paper Journal Title

J Clin Oncol

Paper Citation Count

337

Paper Publication Year

2013

Bio Mention

BRAF, BRAF(, BRAF(V600E), BRAF(V600E) mut, BRAF(V600E) mut(, BRAF(V600E/K), BRAF(V600E/K) mut(+) MM, BRAF(V600K) mut(+) MM, Dabrafenib, GSK2118436, MM, PATIENTS, V600E, V600K, arthralgia, cfDNA, dabrafenib, hyperkeratosis, metastatic melanoma, mut(, mutated BRAF kinase, patients, pyrexia, squamous cell carcinoma, tumor, tumor-specific circulating cell-free DNA, with

Mesh Descriptor

Paper Details

Column Actions

Datasets